AstraZeneca Inks R&D Deal With Ramaswamy's Roivant for Hush-Hush Indication Post author:Sam Post published:October 18, 2017 Post category:BioPharma Vivek Ramaswamy’s parent company, Roivant Sciences, inked a development deal with Astra. Source: BioSpace You Might Also Like Ag Biotech Company Announces $24MM C Round Financing July 9, 2017 Amgen Faces Setback as Osteoporosis Drug is Linked to Serious Heart Side Effects May 21, 2017 CTI BioPharma Reports First Quarter 2017 Financial Results May 3, 2017
